Fastnet approaches an active drill programme in 2013
Paul Griffiths MD at Fastnet Oil & Gas (LON:FAST ESM:FOI) tells Proactiveinvestors that the company goes into its proposed 3-well drill programme with a "strong balance sheet". The company will be...
View ArticleFastnet "positioned well for financial success"
Carol Law, Exec. Director at Fastnet Oil & Gas (LON:FAST). Having been at companies like Cove Energy and Anadarko and been involved with many recent big discoveries in the oil and gas industry in...
View ArticleFastnet MD Paul Griffiths outlines value creation strategy at AGM
Fastnet Oil & Gas MD Paul Griffiths (LON:FAST) outlines the company's performance to date and looks ahead to how Fastnet can create value for shareholders. Paul explains the company's strategy to...
View ArticleFastnet MD sees drilling programme in Morocco as a key driver
Paul Griffiths, MD of Fastnet Oil & Gas (LON:FAST) says that the drill programme planned in Morocco, will be the key share price driver over the next twelve months. Paul also highlights the...
View ArticleHydrocarbon Capital identifies opportunities with small cap oil stocks
Malcolm Graham-Wood, founder of Hydrocarbon Capital, talks through some of the stocks to watch in the small cap oil sector (in order): President Energy (LON:PPC) Andes Energia (LON:AEN) Trinity...
View ArticleRFC Ambrian's Stuart Amor upbeat on Sub-Saharan oil & gas stocks
Stuart Amor, oil & gas analyst at RFC Ambrian, tells Proactiveinvestors he is upbeat on nine Sub-Saharan oil & gas companies. Stuart discusses: Tullow Oil LON:TLW, Ophir LON:OPHR, Africa Oil...
View ArticleFastnet Oil & Gas confident of Celtic Sea farm-out
Will Holland, who joined AIM-listed Fastnet Oil & Gas (LON:FAST) as chief financial officer in May, says the group is confident of securing a farm-in partner for its Celtic Sea licences in the next...
View ArticleFastnet Oil & Gas CFO 'confident' group will attract a Celtic Sea farm-in...
Will Holland, CFO of Fasnet Oil & Gas (LON:FAST), says he is confident the company will attract a farm-in partner in the Celtic Sea. He adds that the company is looking at further acquisition...
View ArticleCantor analyst Sam Wahab on oil price, M&A and small cap tips
Sam Wahab, oil analyst at broker Cantor Fitzgerald, talks about the prospects for the oil industry in 2015, including the potential for more consolidation in the sector. He also names some small and...
View ArticleAmryt Pharmaceuticals’ Episalvan could have “significant commercial success”,...
Joseph Wiley, chief executive elect of Amryt Pharmaceuticals, tells Proactive Investors the company is focused on treatment for rare orphan diseases. Its lead product Episalvan, used to accelerate the...
View ArticleAmryt Pharma chief looking to “unlock a large market opportunity”
Joe Wiley, chief executive of Amryt Pharma PLC (LON:AMYT) says the company is gearing up for a Phase III study for its lead product, Episalvan, for the treatment of epidermolysis bullosa (EB). The...
View ArticleHybridan’s Pearson cautions biotech investors against knee-jerk reactions to...
Hybridan’s Niall Pearson tells biotech investors that drug trial failure is ‘the nature of the beast’ and speaking with Proactive Investors he highlighted examples where selling has gone too far....
View ArticleAmryt Pharmaceuticals’ Joe Wiley on a busy half year in which it acquired EB...
Amryt Pharma chief executive Joe Wiley speaks to Proactive Investors Stocktube about the drug discovery group’s busy half year, which saw two key acquisitions. “We got a huge amount achieved in a...
View ArticleOrphan drug status for new compound 'great news' says Amryt Pharma PLC's COO
Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory...
View ArticleAmryt boss 'really excited' to have signed milestone funding deal
Amryt Pharma plc (LON:AMYT) has secured a €20mln European Investment Bank facility that will help fund a late stage clinical study of a potentially breakthrough treatment for a rare skin disease....
View ArticleAmryt Pharma makes overnight transformation
It’s another day, and another big announcement from Amryt Pharmaceuticals PLC (LON:AMYT), which has unveiled its second major deal in three days. On Friday, the company’s chief executive, Joe Wiley,...
View ArticleAmryt Pharma's COO says Japan patent further boosts potential of lead candidate
Rory Nealon, chief operating officer at drug developer Amryt Pharmaceuticals, tells Proactive that receiving a patent grant in Japan extends the group's patent portfolio for lead drug candidate...
View ArticleCan Amryt Pharma add 75% to its share price?
Shares in Amryt Pharmaceuticals PLC (LON:AMYT) could gain the best part of 75% over the next few months to hit 28p, according to technical analyst Zak Mir. “On the technical front, it looks like...
View ArticleAmryt Pharma's Joe Wiley 'delighted' to soon begin Phase III EB Study
Amryt Pharma PLC (LON:AMYT) chief executive Joe Wiley tells Proactive they'll soon begin a phase III clinical trial on a drug for people with a rare skin disorder following the completion of...
View ArticleAmryt Pharma can go as high as 30p, says Zak Mir
Leading technical analyst Zak Mir tells the Proactive Investors Bulletin Board he is looking for the Amryt Pharmaceuticals PLC (LON:AMYT) share price to hit 30p in the coming months. “There’s been a...
View Article
